Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years.
Alessia RomagnoliFiorenzo SantoleriAlberto CostantiniAngelora Di RisioPublished in: European journal of hospital pharmacy : science and practice (2022)
The data collected over a 3-year period showed that adherence and persistence levels and switch data were optimal and comparable in patients with non-valvular atrial fibrillation receiving treatment with either rivaroxaban or apixaban. In contrast, patients treated with dabigatran had worrying adherence and persistence levels.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- electronic health record
- heart failure
- percutaneous coronary intervention
- big data
- glycemic control
- clinical trial
- magnetic resonance
- type diabetes
- data analysis
- magnetic resonance imaging
- cross sectional
- machine learning
- skeletal muscle
- contrast enhanced
- weight loss